CD274 and neoplasm: Recently, a nanovesicle was engineered with anti-PD-L1 scFvs on its surface, enabling binding to programmed death-ligand (PD-L1) expressed on tumor cells.91 Once bound, the nanovesicle delivers a glutamine antagonist, inhibiting tumor growth.